Akero Therapeutics, Inc. (NASDAQ:AKRO) Insider Catriona Yale Sells 614 Shares of Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) insider Catriona Yale sold 614 shares of Akero Therapeutics stock in a transaction on Wednesday, March 12th. The shares were sold at an average price of $44.88, for a total value of $27,556.32. Following the transaction, the insider now owns 95,034 shares of the company’s stock, valued at $4,265,125.92. The trade was a 0.64 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Catriona Yale also recently made the following trade(s):

• On Tuesday, February 18th, Catriona Yale sold 10,000 shares of Akero Therapeutics stock. The stock was sold at an average price of $49.87, for a total value of $498,700.00.
• On Monday, December 16th, Catriona Yale sold 9,074 shares of Akero Therapeutics stock. The stock was sold at an average price of $29.11, for a total value of $264,144.14.

Akero Therapeutics Stock Performance

NASDAQ:AKRO opened at $44.15 on Friday. The stock has a 50-day simple moving average of $42.10 and a two-hundred day simple moving average of $33.79. Akero Therapeutics, Inc. has a 52-week low of $17.86 and a 52-week high of $58.40. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25. The firm has a market capitalization of $3.52 billion, a PE ratio of -11.77 and a beta of -0.19.

Akero Therapeutics (NASDAQ:AKRO) last released its quarterly earnings results on Friday, February 28th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.98) by ($0.01). Analysts forecast that Akero Therapeutics, Inc. will post -3.99 EPS for the current year.

Analyst Ratings Changes

AKRO has been the subject of several recent analyst reports. Canaccord Genuity Group boosted their price target on Akero Therapeutics from $56.00 to $73.00 and gave the stock a “buy” rating in a research note on Tuesday, January 28th. Morgan Stanley restated an “overweight” rating on shares of Akero Therapeutics in a research note on Sunday, March 2nd. Citigroup upped their price objective on Akero Therapeutics from $65.00 to $80.00 and gave the company a “buy” rating in a research report on Tuesday, January 28th. Bank of America upgraded Akero Therapeutics from a “neutral” rating to a “buy” rating and upped their price objective for the company from $35.00 to $63.00 in a research report on Thursday, January 30th. Finally, HC Wainwright upped their price objective on Akero Therapeutics from $72.00 to $75.00 and gave the company a “buy” rating in a research report on Monday, March 3rd. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $76.29.

Hedge Funds Weigh In On Akero Therapeutics

A number of hedge funds have recently made changes to their positions in the business. Summit Investment Advisors Inc. boosted its stake in shares of Akero Therapeutics by 6.8% in the fourth quarter. Summit Investment Advisors Inc. now owns 7,092 shares of the company’s stock worth $197,000 after acquiring an additional 450 shares during the period. Hsbc Holdings PLC boosted its stake in shares of Akero Therapeutics by 8.5% in the fourth quarter. Hsbc Holdings PLC now owns 7,886 shares of the company’s stock worth $220,000 after acquiring an additional 621 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in shares of Akero Therapeutics by 1.6% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 41,442 shares of the company’s stock worth $1,153,000 after acquiring an additional 637 shares during the period. Handelsbanken Fonder AB lifted its position in shares of Akero Therapeutics by 5.0% in the fourth quarter. Handelsbanken Fonder AB now owns 21,000 shares of the company’s stock worth $584,000 after buying an additional 1,000 shares in the last quarter. Finally, Swiss National Bank lifted its position in shares of Akero Therapeutics by 1.2% in the fourth quarter. Swiss National Bank now owns 95,600 shares of the company’s stock worth $2,660,000 after buying an additional 1,100 shares in the last quarter.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.